Hypertension
Nov 26, 2008 13:00 EST
In the largest study of its kind to date, Brazilian researchers have shown that ambulatory BP monitoring is a predictor of future cardiovascular events in patients with resistant hypertension, but office BP is not. (Salles GF et al. Arch Intern Med 2008; 168:2340-2346.)

Rio de Janeiro, Brazil - In the largest study of its kind to date, Brazilian researchers have shown that continually monitoring blood pressure (BP)—called ambulatory BP monitoring (ABPM)—is a predictor of future cardiovascular events in patients with resistant hypertension, but office BP is not [1]. Dr Gil F Salles (University Hospital Clementino Fraga Filho, Rio de Janeiro, Brazil) and colleagues report their findings in the November 24, 2008 issue of the Archives of Internal Medicine. Read full article »

(Salles GF et al. Arch Intern Med 2008; 168:2340-2346.)
Inside: Hypertension
Accredited educational programs, supported by industry, developed by theheart.org

 
Clinical cardiology
5 COMMENTS - Dec 2, 2008 16:00 EST
Twenty years of research show that generic CVD drugs across nine classes are just as good as brand-name agents, yet editorials often boost superiority of brand-name agents. (Kesselheim AS et al. JAMA 2008; 300:2514-2526.)
Lipid/Metabolic
Dec 2, 2008 13:30 EST
It's not just the amount of alcohol is drunk, but the way that it is drunk that is important when it comes to cardiovascular health. New research suggests a precise mechanism by which binge drinking might contribute to atherosclerosis. (Redmond EM et al. Atherosclerosis; published online before print October 18, 2008.)
MediaPulse
10 COMMENTS - Nov 28, 2008 15:30 EST
Six years after the 44 000-patient trial was reported, use of generic diuretics never reached the levels that investigators expected. Reasons include patents ending, new drugs emerging, and the advent of combination pills, but also the millions of dollars spent by companies making brand-name antihypertensives.
Hypertension
Nov 27, 2008 17:00 EST
Two new studies published online this week help shed light on the off-target toxicity of the CETP inhibitor torcetrapib, but the studies conflict regarding the atheroprotective functionality of the HDL cholesterol resulting with the drug. (Vergeer M et al. Nicholls SJ et al. Circulation; published online before print November 25, 2008.)
Heart failure
Nov 24, 2008 16:00 EST
One of the largest and most comprehensive studies of heart failure to date in Africa has shown that the disease is a big problem and that although the traditional causes of HF—which differ from those seen in Western nations—still predominate, there are signs that the range of etiologies is broadening (Stewart S et al. Circulation 2008; published online before print November 24, 2008.)
Clinical cardiology
Nov 21, 2008 13:00 EST
The first study to ever assess the prognostic value of a change in heart rate over a number of years has found that increasing HR over time can increase mortality, by around 20%. Conversely, a decline in HR was accompanied by reduced rate of death over the five-year study period. (Jouven et al. Am J Cardiol; published online before print November 7, 2008.)
Hypertension
3 COMMENTS - Nov 21, 2008 10:15 EST
Chlorthalidone and lisinopril as initial antihypertensive agents were about equally effective at reducing the risk of new systolic heart failure, an analysis suggests; the thiazide was superior at preventing heart failure with preserved EF. (Davis BR et al. Circulation; published online before print November 10, 2008.)
Prevention
Nov 14, 2008 16:45 EST
Researchers who fitted study subjects with "air-pollution vests" to continuously monitor exposure to both indoor and outdoor air pollutants say that people are probably exposed to much higher levels of pollutants than community monitoring stations typically indicate and that this exposure affects both endothelial function and systolic blood pressure. (American Heart Association 2008 Scientific Sessions.)
Interventional/Surgery
3 COMMENTS - Nov 12, 2008 14:00 EST
The use of beta blockers perioperatively to prevent cardiovascular events in patients undergoing noncardiac surgery is not justified by current evidence, according to the authors of a new meta-analysis. An update to the guidelines on this issue is under way, says one member of the writing committee, who incidentally does not agree with this overall conclusion. (Bangalore S et al. Lancet; published online before print November 12, 2008. American Heart Association 2008 Scientific Sessions.)
Heart failure
7 COMMENTS - Nov 12, 2008 10:45 EST
Four years of treatment with irbesartan, usually on top of other drugs that affect the renin-angiotensin-aldosterone system, didn't improve outcomes in patients with the common but poorly understood form of heart failure. The trial follows previous negative studies of an ACE inhibitor and a different angiotensin-receptor blocker, respectively, in similar populations. (American Heart Association 2008 Scientific Sessions.)
Hypertension
7 COMMENTS - Nov 11, 2008 13:30 EST
Results of a small randomized trial show that hibiscus tea given three times daily reduced systolic blood pressure by about 7 mm Hg in prehypertensive and mildly hypertensive subjects. (American Heart Association 2008 Scientific Sessions.)
Prevention
Nov 6, 2008 18:30 EST
Focusing on the classic risk factors for coronary heart disease and ensuring that best-practice interventions to reduce absolute risk are implemented across the board could largely eliminate socioeconomic differences in CHD deaths, a new British study predicts (Kivimäki M et al. Lancet 2008; 372:1648-1654.)
Association partnership
This section is presented in collaboration with the
Resource center
Poll
Who is your most challenging patient type to treat/reach BP goal?

Elderly (>75 years of age)
African American
Diabetic
other

Previews
Info from Industry